Bio Rad Laboratories Inc
NYSE:BIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bergs Timber AB (publ)
STO:BRG B
|
SE |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (26.6), the stock would be worth $274.13 (9% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 29.1 | $300.78 |
0%
|
| 3-Year Average | 26.6 | $274.13 |
-9%
|
| 5-Year Average | 27.4 | $282.83 |
-6%
|
| Industry Average | 23.5 | $242.55 |
-19%
|
| Country Average | 14.4 | $148.17 |
-51%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$7.2B
|
/ |
Jan 2026
$266.1m
|
= |
|
|
$7.2B
|
/ |
Dec 2026
$455.1m
|
= |
|
|
$7.2B
|
/ |
Dec 2027
$489.7m
|
= |
|
|
$7.2B
|
/ |
Dec 2028
$535.4m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Bio Rad Laboratories Inc
NYSE:BIO
|
8.1B USD | 29.1 | 10.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 225.9 | 4 278.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.4B USD | 19.9 | 28.8 | |
| US |
|
Danaher Corp
NYSE:DHR
|
130.1B USD | 18.4 | 36 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 30.1 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
35.1B CHF | 16.9 | -124.9 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
294B CNY | 16.1 | 15.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD | 19.4 | 26.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.8B USD | 32.9 | 51 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.7B USD | 12.1 | 22 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.7B USD | 22.7 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Bio Rad Laboratories Inc
Glance View
Bio-Rad Laboratories Inc. began its journey in 1952 and has since positioned itself as a formidable player in the life sciences and clinical diagnostics sectors. Founded by David and Alice Schwartz, the company thrived on the burgeoning interest in biological research, carving a niche by supplying essential products to scientists and healthcare professionals. With its headquarters in Hercules, California, Bio-Rad has continually developed a suite of innovative solutions that cater to both academic research and the intricate needs of clinical diagnostics, paving its way to becoming a global leader. Their operations are distinctly bifurcated: Life Science, which focuses on products for gene expression, protein purification, and food safety, and Clinical Diagnostics, offering tools for blood testing and diabetes monitoring. The core of Bio-Rad’s business model lies in its ability to design and manufacture advanced technological products that streamline laboratory processes, making research and diagnostics more efficient and reliable. The Life Science segment generates revenue by selling reagents, lab instruments, and software that facilitate various laboratory protocols and experiments, assisting scientists in their pursuit of breakthroughs in biotechnology and pharmaceutical development. Meanwhile, the Clinical Diagnostics segment garners earnings through the provision of innovative testing and analysis tools that enable accurate disease diagnosis, blood analysis, and quality control. Guided by a robust infrastructure of research and development, the company continuously adapts to the evolving demands of science and healthcare, maintaining its fiscal health while reinforcing its reputation as a trusted provider in the global market.
